by These products containing low glycemic carbohydrates, high-fiber ingredients, and other macronutrients are an important component of diabetes management plans prescribed by healthcare providers and dietitians globally.
The Global Diabetes Nutrition Market is estimated to be valued at US$ 6588.59 Mn in 2024 and is expected to exhibit a CAGR of 4.0% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the diabetes nutrition market are Actavis, AbbVie Inc., Astellas Pharma Inc., Cara Therapeutics, EPI Health LLC, Galderma Laboratories LP, Ocera Therapeutics Inc., and Pfizer Inc., Sanofi, Trevi Therapeutics. These companies offer a wide range of nutrition products targeting different stages of diabetes care and treatment.
The growing incidence of diabetes worldwide mainly due to obesity, sedentary lifestyles and unhealthy dietary habits is expected to drive the demand for diabetes-specific nutritional foods and beverages. Diabetes management requires lifestyle modifications, including modifications to diet, and nutritional products help achieve blood sugar control in a more convenient way.
Globally, North America dominated the Diabetes Nutrition Market Size in 2020. However, Asia Pacific is expected to witness the highest growth during the forecast period owing to the rapid economic development and rising health awareness in populous countries such as China and India resulting in higher disposable incomes. However, other emerging regions are also witnessing increased adoption of nutritional therapies in diabetes care.
Market key trends
One of the key trends witnessed in the diabetes nutrition market is the shift towards preventive care and disease management through dietary modifications instead of drugs alone. Various startups are developing innovative low-calorie plant-based foods with specialized macronutrient profiles that help control blood glucose levels and reduce the risk of diabetes. Advancements in formulation technologies are also enabling the development of more effective nutritional therapies for better management of diabetes and its complications long-term.
Porter’s Analysis
Threat of new entrants: The high cost associated with R&D makes the threat low.
Bargaining power of buyers: The buyers have high bargaining power due to the availability of generic medicines.
Bargaining power of suppliers: Pharmaceutical companies have a moderate level of control over raw material suppliers.
Threat of new substitutes: There exist potential substitute treatments that may threaten the market.
Competitive rivalry: The competition is intense among the existing key players in the market.
The North American region accounts for the largest share in the diabetes nutrition market in terms of value owing to increased production of diabetes nutritional products, growing advancement in diabetes treatment and greater healthcare spending in this region. The Asia Pacific region is expected to grow at the fastest rate during the forecast period due to rising incidence of diabetes, increasing awareness about diabetes management, growing healthcare expenditure and expansion of key players in emerging markets.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
